CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Pszczyna, Poland

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

    Phase

    3

    Span

    115 weeks

    Sponsor

    Novo Nordisk A/S

    Krosno

    Recruiting

  • Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

    Phase

    4

    Span

    195 weeks

    Sponsor

    Wroclaw Medical University

    Krosno, Podkarpackie

    Recruiting

  • Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

    The study consists of 4 periods, and the total study duration is up to 112 weeks. Approximately 468 adult participants with CSU are expected to be randomized in the study. Screening period: A screening period of up to 4 weeks will allow for the assessment of eligibility, determination of baseline disease activity and wash-out of prohibited medications. Core Phase Treatment Period (52 weeks): The treatment period will be double-dummy and double-blind, with placebo injections matching omalizumab 300 mg s.c. given to participants in the remibrutinib arm and placebo tablets matching remibrutinib 25 mg given to participants in the omalizumab arm (double-dummy). At the randomization visit, eligible participants will be randomized to one of four treatment arms. Extension Phase Treatment Period (52 weeks): Optional open-label extension where patients receive treatment with open-label remibrutinib 25 mg, for 52 weeks. Follow-up period: For patients that do not enter the extension phase, there will be a 16-week, treatment-free, safety follow-up period. Patients that enter extension phase will have a 4-week treatment-free safety follow-up period at the end of the extension phase. All participants will be on a stable, local label-approved standard dose of a second-generation H1-AH ("background therapy") throughout the entire core phase (starting a minimum of 7 days prior to randomization until the end of the core phase). In addition, to treat unbearable symptoms of CSU flare-ups, participants will be allowed to use a different second-generation H1-AH on an as-needed basis ("rescue therapy").

    Phase

    3

    Span

    192 weeks

    Sponsor

    Novartis Pharmaceuticals

    Krosno

    Recruiting

  • A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

    Phase

    3

    Span

    217 weeks

    Sponsor

    Novo Nordisk A/S

    Krosno

    Recruiting

1-4 of 4
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information